Persistent Opioid Use After Cardiac Implantable Electronic Device Procedures
Author(s) -
Timothy M. Markman,
Chase R. Brown,
Lin Yang,
Gustavo S. Guandalini,
Matthew C. Hyman,
Jeffrey Arkles,
Pasquale Santangeli,
Robert D. Schaller,
Gregory E. Supple,
Rajat Deo,
Saman Nazarian,
Sanjay Dixit,
David J. Callans,
Andrew E. Epstein,
Francis E. Marchlinski,
Peter W. Groeneveld,
David S. Frankel
Publication year - 2021
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.121.055524
Subject(s) - medicine , opioid , anesthesia , opioid epidemic , cardiology , intensive care medicine , receptor
Background: Prescription opioids are a major contributor to the ongoing epidemic of persistent opioid use (POU). The incidence of POU among opioid-naïve patients after cardiac implantable electronic device (CIED) procedures is unknown. Methods: This retrospective cohort study used data from a national administrative claims database from 2004 to 2018 of patients undergoing CIED procedures. Adult patients were included if they were opioid-naïve during the 180-day period before the procedure and did not undergo another procedure with anesthesia in the next 180 days. POU was defined by filling an additional opioid prescription >30 days after the CIED procedure. Results: Of the 143 400 patients who met the inclusion criteria, 15 316 (11%) filled an opioid prescription within 14 days of surgery. Among these patients, POU occurred in 1901 (12.4%) patients 30 to 180 days after surgery. The likelihood of developing POU was increased for patients who had a history of drug abuse (odds ratio, 1.52;P =0.005), preoperative muscle relaxant (odds ratio, 1.52;P <0.001) or benzodiazepine (odds ratio, 1.23;P =0.001) use, or opioid use in the previous 5 years (OR, 1.76;P <0.0001). POU did not differ after subcutaneous implantable cardioverter defibrillator or other CIED procedures (11.1 versus 12.4%;P =0.5). In a sensitivity analysis excluding high-risk patients who were discharged to a facility or who had a history of drug abuse or previous opioid, benzodiazepine, or muscle relaxant use, 8.9% of the remaining cohort had POU. Patients prescribed >135 mg of oral morphine equivalents had a significantly increased risk of POU.Conclusions: POU is common after CIED procedures, and 12% of patients continued to use opioids >30 days after surgery. Higher initially prescribed oral morphine equivalent doses were associated with developing POU.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom